SMS Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients (APIs) and its intermediates in India and internationally. It offers anti-retroviral, anti-inflammatory, anti-viral, anti-diabetic, anti-fungal, anti-epileptic, anti-migraine, anti-coagulant, anti-psychotic, anti-aginal, and anti-ulcer products. It is also involved in contract research activities on peptides. The ...
SMS Pharmaceuticals reported revenue of 7.83 billion INR for fiscal year 2025, up 10.4% from fiscal year 2024, and net income of 691.35 million INR. In Q3 2026 (the quarter ended December 31, 2025) revenue was 2.10 billion INR, up 21.4% from a year before. Exports was its largest region in fiscal year 2025, with 69% of revenue. Its market capitalization was 41.64 billion INR as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended March 31, 2025; market data as of October 9, 2026.
No profile data available.